The landscape of metabolic research has been fundamentally altered by the emergence of incretin mimetics. While Semaglutide has long been the gold standard for GLP-1 receptor agonism, Tirzepatide introduces a "twincretin" approach by targeting both G...

The landscape of metabolic research has shifted significantly with the development of specific signaling molecules known as Growth Hormone Secretagogues (GHS). Among these, the Ipamorelin peptide stands out as one of the most selective and stable com...

Glucagon-like peptide-1 (GLP-1) represents a critical frontier in metabolic and endocrine research. As an incretin hormone derived from the proglucagon gene, these peptides play a fundamental role in glucose homeostasis and systemic metabolic regulat...

Retatrutide (LY3437943) represents a significant evolution in the landscape of metabolic research and peptide science. While previous generations of metabolic regulators focused on single or dual hormone pathways, Retatrutide is the first widely reco...

Technical guide to semaglutide: Understand its GLP-1 mechanism, molecular engineering, and clinical efficacy in metabolic weight management research.

In today's global fitness craze, more and more fitness enthusiasts and professional athletes are turning their attention to highly effective and safe nutritional supplements. Among them, testosterone ester powders, considered the "golden trio" of the...

As the new year begins, ACDCraw Source Co., Ltd. (hereinafter referred to as "ACDC raw Source"), a leading pharmaceutical and fitness ingredient supplier in China, officially released a major announcement: In 2026, the company will see an explos...

★The Call of Cutting Season, the Return of Masteron★As the new year begins and the clock strikes midnight on 2026, gyms are already buzzing with activity. Countless bodybuilding enthusiasts and professional athletes are gearing up for a new round...

Tilpotide is a dual targeted heavy blood glucose lowering drug.On May 21, 2024, the official website of the State Food and Drug Administration showed that Lilly's double target weight-loss hypoglycemic drug Tilpoltide was approved for marketing, ...

Tilpotide is the world's first and currently the only GIP/GLP-1 receptor agonist.This approval is mainly based on the global key phase III registration trial named SURPASS 1-5 and the Asia Pacific key phase III registration trial named SURPASS AP...